Defining the role of trimetazidine in the treatment of cardiovascular disorders: Some insights on its role in heart failure and peripheral artery disease

Drugs

Volumn 74, Issue 9, 2014, Pages 971-980

  Chrusciel, Piotr ^a   Rysz, Jacek ^a   Banach, MacIej ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; METOPROLOL; PLACEBO; TRIMETAZIDINE; CARDIOVASCULAR AGENT;

AGRANULOCYTOSIS; CARDIOLOGY; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; DRUG USE; DRUG WITHDRAWAL; EUROPE; EXTRAPYRAMIDAL SYMPTOM; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; LIVER DYSFUNCTION; MEDICAL SOCIETY; META ANALYSIS; NAUSEA; PARKINSONISM; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREMOR; VOMITING; CARDIOVASCULAR DISEASES; PERIPHERAL ARTERIAL DISEASE;

PARKINSONIA;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; HEART FAILURE; HUMANS; PERIPHERAL ARTERIAL DISEASE; TRIMETAZIDINE;

EID: 84904069332     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0233-5     Document Type: Review

References (72)

1. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000;86:580-8.
2. Fantini E, Demaison L, Sentex E, Grynberg A, Athias P. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol. 1994;26:949-58.
3. Banach M. The role of trimetazidine in the treatment of heart diseases. Poznan: Termedia Publishing House; 2006.
4. Lopez N, Varo N, Diez J, Fortuno MA. Loss of myocardial LIF receptor in experimental heart failure reduces cardiotrophin-1 cytoprotection. A role for neurohumoral agonists? Cardiovasc Res. 2007;75:536-45.
5. Parang P, Singh B, Arora R. Metabolic modulators for chronic cardiac ischemia. J Cardiovasc Pharmacol Ther. 2005;10:217-23.
6. Kowalski J, Pawlicki L, Baj Z, Paśnik J, Olejniczak J. Effect of trimetazidine on biological activity of neutrophils in patients with transient myocardial ischemia induced by exercise testing. Pol Merkuriusz Lek. 2000;9:548-51.
7. Kiyosue T, Nakamura S, Arita M. Effects of trimetazidine on action potentials and membrane currents of guinea-pig ventricular myocytes. J Mol Cell Cardiol. 1986;18:1301-11.
8. Onay-Besikci A, Ozkan SA. Trimetazidine revisited: a comprehensive review of the pharmacological effects and analytical techniques for the determination of trimetazidine. Cardiovasc Ther. 2008;26(2):147-65.
9. Liu X, Gai Y, Liu F, Gao W, Zhang Y, Xu M, Li Z. Trimetazidine inhibits pressure overload-induced cardiac fibrosis through NADPH oxidase-ROS-CTGF pathway. Cardiovasc Res. 2010;88(1):150-8.
10. Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:347-54.
11. Ruiz-Meana M, Garcia-Dorado D, Julia M, et al. Pre-treatment with trimetazidine increases sarcolemmal mechanical resistance in reoxygenated myocytes. Cardiovasc Res. 1996;32:587-92.
12. Ruixing YH. The role of trimetazidine in inhibiting cardiomyocyte apoptosis. Arch Med Sci. 2007;3:S17-24.
13. Argaud L, Gomez L, Gateau-Roesch O, Couture-Lepetit E, Loufouat J, Robert D, Ovize M. Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia-reperfusion injury. J Mol Cell Cardiol. 2005;39:893-999.
14. Athyros VG, Gossios TD, Tziomalos K, Florentin M, Karagiannis A, Mikhailidis DP. Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment? Arch Med Sci. 2011;7:1067-75.
15. Szwed H, Sadowski Z, Elikowski W, Koronkiewicz A, Mamcarz A, Orszulak W, Skibińska E, Szymczak K, Swiatek J, Winter M. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J. 2001;22:2267-74.
16. Szwed H, Pachocki R, Domzal-Bochenska M, Szymczak K, Szydlowski Z, Paradowski A, Gajos G, Kaluza G, Kulon I, Wator-Brzezińska A, Elikowski W, Kuźniak M. Efficacy and tolerance of trimetazidine, a metabolic antianginal, in combination with a hemodynamic antianginal in stable exertion angina. TRIMPOL I, a multicenter study. Presse Med. 2000;29:533-8.
17. Sellier P, Broustet JP. Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study. Am J Cardiovasc Drugs. 2003;3:361-9.
18. Vitale C, Spoletini I, Malorni W, Perrone-Filardi P, Volterrani M, Rosano GM. Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina - the VASCO-angina study. Int J Cardiol. 2013;168:1078-81.
19. Manchanda SC, Krishnaswami S. Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart. 1997;78:353-7.
20. Manchanda SC. Treatment of stable angina with low dose diltiazem in combination with the metabolic agent trimetazidine. Int J Cardiol. 2003;88:83-9.
21. Marzilli M, Klein WW. Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials. Coronary Artery Dis. 2003;14:171-9.
22. Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev. 2005:CD003614.
23. Danchin N, Marzilli M, Parkhomenko O, Ribeiro JP. Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta-analysis. Cardiology. 2011;120:59-72.
24. European Medicines Agency recommends restricting use of trimetazidine-containing medicines. Press release. European Medicines Agency; 2012.
25. Kowalski J, Banach M, Barylski M, Irzmanski R, Pawlicki L. Carvedilol modifies antioxidant status of patients with stable angina. Cell Mol Biol Lett. 2008;13:230-9.
26. Brottier L, Barat JL, Combe C, et al. Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy. Eur Heart J. 1990;11:207-12.
27. Lu C, Dabrowski P, Fragasso G, Chierchia SL. Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol. 1998;82:898-901.
28. Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur Heart J. 2001;22:2164-70.
29. Fragasso G, Piatti PM, Monti L, et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J. 2003;146(E18):1-8.
30. Rosano GM, Vitale C, Sposato B, Mercuro G, Fini M. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol. 2003;2:1-9.
31. El-Kady T, El-Sabban K, Gabaly M, Sabry A, Abdel-Hady S. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am J Cardiovasc Drugs. 2005;5:271-8.
32. Morgan EE, Young ME, McElfresh TA, Kung TA, Hoit BD, Chandler MP, Stanley WC. Chronic treatment with trimetazidine reduces the upregulation of atrial natriuretic peptide in heart failure. Fundam Clin Pharmacol. 2006;20:503-5.
33. Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor in patients with heart failure. J Am Coll Cardiol. 2006;48:992-8.
34. Di Napoli P, Di Giovanni P, Gaeta MA, D'Apolito G, Barsotti A. Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy. Am Heart J. 2007;154:602.e1-5.
35. Sisakian H, Torgomyan A, Barkhudaryan A. The effect of trimetazidine on left ventricular systolic function and physical tolerance in patients with ischaemic cardiomyopathy. Acta Cardiol. 2007;62:493-9.
36. Belardinelli R, Solenghi M, Volpe L, Purcaro A. Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect. Eur Heart J. 2007;28:1102-8.
37. Tuunanen H, Engblom E, Naum A, Någren K, Scheinin M, Hesse B, et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation. 2008;118:1250-8.
38. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res. 2012;51:314-24.
39. Serban C, Muntean D, Mikhailids DP, Toth PP, Banach M. Dysfunctional HDL: the journey from savior to slayer. Clin Lipidol. 2014;9:49-59.
40. Barylski M, Toth PP, Nikolic D, Banach M, Rizzo M, Montalto G. Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. Best Pract Res Clin Endocrinol Metab. 2014;28(3):453-461.
41. Fragasso G, Salerno A, Lattuada G, Cuko A, Calori G, Scollo A, et al. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure. Heart. 2011;97:1495-500.
42. Thrainsdottir IS, von Bibra H, Malmberg K, Rydén L. Effects of trimetazidine on left ventricular function in patients with type 2 diabetes and heart failure. J Cardiovasc Pharmacol. 2004;44:101-8.
43. Gunes Y, Guntekin U, Tuncer M, Sahin M. Improved left and right ventricular functions with trimetazidine in patients with heart failure: a tissue Doppler study. Heart Vessels. 2009;24:277-82.
44. Wenmeng W, Qizhu T. Early administration of trimetazidine may prevent or ameliorate diabetic cardiomyopathy. Med Hypotheses. 2011;76:181-3.
45. Stepien M, Stepien A, Wlazel RN, Paradowski M, Rizzo M, Banach M, Rysz J. Predictors of insulin resistance in patients with obesity: a pilot study. Angiology. 2014;65:22-30.
46. Stȩpień M, Wlazeł RN, Paradowski M, Banach M, Rysz M, Misztal M, Rysz J. Serum concentrations of adiponectin, leptin, resistin, ghrelin and insulin and their association with obesity indices in obese normo- and hypertensive patients - pilot study. Arch Med Sci. 2012;8:431-6.
47. Gunes Y, Guntekin U, Tuncer M, Sahin M. The effects of trimetazidine on heart rate variability in patients with heart failure. Arq Bras Cardiol. 2009;93:154-8.
48. Gunes Y, Tuncer M, Guntekin U, Akdag S, Gumrukcuoglu HA. The effects of trimetazidine on p-wave duration and dispersion in heart failure patients. Pacing Clin Electrophysiol. 2009;32:239-44.
49. Mariscalco G, Klersy C, Zanobini M, Banach M, Ferrarese S, Borsani P, Cantore C, Biglioli P, Sala A. Atrial fibrillation after isolated coronary surgery affects late survival. Circulation. 2008;118:1612-8.
50. Zemljic G, Bunc M, Vrtovec B. Trimetazidine shortens QTc interval in patients with ischemic heart failure. J Cardiovasc Pharmacol Ther. 2010;15:31-6.
51. Cera M, Salerno A, Fragasso G, Montanaro C, Gardini C, Marinosci G, et al. Beneficial electrophysiological effects of trimetazidine in patients with postischemic chronic heart failure. J Cardiovasc Pharmacol Ther. 2010;15:24-30.
52. Di Napoli P, Di Giovanni P, Gaeta MA, Taccardi AA, Barsotti A. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pinid'Abruzzo Trimetazidine Trial. J Cardiovasc Pharmacol. 2007;50:585-9.
53. Gao D, Ning N, Niu X, Hao G, Meng Z. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart. 2011;97:278-86.
54. Zhang L, Lu Y, Jiang H, Zhang L, Sun A, Zou Y, Ge J. Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. J Am Coll Cardiol. 2012;59:913-22.
55. Fragasso G, Rosano G, Baek SH, Sisakian H, Di Napoli P, Alberti L, et al. Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicenter retrospective cohort study. Int J Cardiol. 2013;163:320-5.
56. Syrkin AL, Artiukhina EG, Kanorskii SG, Chuntyzheva MM. Antiischemic efficacy of trimetazidine in patients with intermittent claudication and effort angina. Kardiologiia. 2003;43:49-52.
57. Ma A, Garland WT, Smith WB, Skettino S, Navarro MT, Chan AQ, et al. A pilot study of ranolazine in patients with intermittent claudication. Int Angiol. 2006;25:361-9.
58. Vitale C, Marazzi G, Pelliccia F, Volterrani M, Cerquetani E, Spoletini I, et al. Trimetazidine improves exercise performance in patients with peripheral arterial disease. Pharmacol Res. 2011;63:278-83.
59. Mohand-Said S, Jacquet A, Lucien A, Espinasse-Berrod MA, Frasson Correa De Silva M, Sahel J. Protective effect of trimetazidine in a model of ischemia-reperfusion in the rat retina. Ophthalmic Res. 2002;34:300-5.
60. Yoon JW, Cho BJ, Park HS, Kang SM, Choi SH, Jang HC, et al. Differential effects of trimetazidine on vascular smooth muscle cell and endothelial cell in response to carotid artery balloon injury in diabetic rats. Int J Cardiol. 2013;167:126-33.
61. Martí Massó JF, Martí I, Carrera N, Poza JJ, de López Munain A. Trimetazidine induces parkinsonism, gait disorders and tremor. Therapie. 2005;60:419-22.
62. Barré J, Ledudal P, Oosterhuis B, Brakenhoff JP, Wilkens G, Sollie FA, Tran D. Pharmacokinetic profile of a modified release formulation of trimetazidine (TMZ MR 35 mg) in the elderly and patients with renal failure. Biopharm Drug Dispos. 2003;24:159-64.
63. Members Task Force, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;2013(34):2949- 3003.
64. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K. ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787-847.
65. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H. ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2999-3054.
66. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569-619.
67. European Stroke Organisation, Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Clément D, Collet JP. ESC Committee for Practice Guidelines. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2851-906.
68. Filippatos TD, Rizos EC, Gazi IF, Lagos K, Agouridis D, Mikhailidis DP, Elisaf MS. Differences in metabolic parameters and cardiovascular risk between American Diabetes Association and World Health Organization definition of impaired fasting glucose in European Caucasian subjects: a cross-sectional study. Arch Med Sci. 2013;9:788-95.
69. Vitale C, Iellamo F, Volterrani M, Lombardi M, Fini M, Banach M, Rosano GM. Heart rate control in an unselected consecutive population of outpatients with stable coronary artery disease: analysis of the CARDIf Study Cohort. Angiology. 2010;61:763-7.
70. Franczyk-Skóra B, Gluba A, Banach M, Rysz J. Treatment of non-ST-elevation myocardial infarction and ST-elevation myocardial infarction in patients with chronic kidney disease. Arch Med Sci. 2013;9:1019-27.
71. Banach M, Serban C, Aronow WS, Rysz J, Dragan S, Lerma EV, Apetrii M, Covic A. Lipid, blood pressure and kidney update 2013. Int Urol Nephrol. 2014;46:947-61.
72. Banach M, Rysz J, Goch A, Mikhailidis DP, Rosano GM. The role of trimetazidine after acute myocardial infarction. Curr Vasc Pharmacol. 2008;6:282-91.